These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 8568807

  • 1. In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter.
    Lee LC, Vander Borght T, Sherman PS, Frey KA, Kilbourn MR.
    J Med Chem; 1996 Jan 05; 39(1):191-6. PubMed ID: 8568807
    [Abstract] [Full Text] [Related]

  • 2. In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies.
    Kilbourn MR, Sherman PS, Kuszpit K.
    Synapse; 2002 Mar 01; 43(3):188-94. PubMed ID: 11793424
    [Abstract] [Full Text] [Related]

  • 3. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR, Kuszpit K, Sherman P.
    Synapse; 2000 Mar 15; 35(4):250-5. PubMed ID: 10657034
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain.
    Kilbourn MR, Kemmerer ES, Desmond TJ, Sherman PS, Frey KA.
    Exp Neurol; 2004 Aug 15; 188(2):387-90. PubMed ID: 15246838
    [Abstract] [Full Text] [Related]

  • 5. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter.
    Koeppe RA, Frey KA, Vander Borght TM, Karlamangla A, Jewett DM, Lee LC, Kilbourn MR, Kuhl DE.
    J Cereb Blood Flow Metab; 1996 Nov 15; 16(6):1288-99. PubMed ID: 8898703
    [Abstract] [Full Text] [Related]

  • 6. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
    Staal RG, Hogan KA, Liang CL, German DC, Sonsalla PK.
    J Pharmacol Exp Ther; 2000 May 15; 293(2):329-35. PubMed ID: 10772999
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands.
    Zheng P, Lieberman BP, Choi SR, Plöessl K, Kung HF.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3435-8. PubMed ID: 21531556
    [Abstract] [Full Text] [Related]

  • 8. Amino- and amido-tetrabenazine derivatives: synthesis and evaluation as potential ligands for the vesicular monoamine transporter.
    Canney DJ, Kung MP, Kung HF.
    Nucl Med Biol; 1995 May 01; 22(4):527-35. PubMed ID: 7550031
    [Abstract] [Full Text] [Related]

  • 9. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
    Brown JM, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2001 Sep 01; 298(3):1150-3. PubMed ID: 11504813
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.
    Kolhatkar RB, Ghorai SK, George C, Reith ME, Dutta AK.
    J Med Chem; 2003 May 22; 46(11):2205-15. PubMed ID: 12747792
    [Abstract] [Full Text] [Related]

  • 12. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L, Crooks PA, Dwoskin LP.
    J Neurochem; 1998 Jul 22; 71(1):258-65. PubMed ID: 9648873
    [Abstract] [Full Text] [Related]

  • 13. In vivo imaging of the brain vesicular monoamine transporter.
    Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, Frey KA.
    J Nucl Med; 1995 Dec 22; 36(12):2252-60. PubMed ID: 8523116
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters.
    Kilbourn MR, Frey KA, Vander Borght T, Sherman PS.
    Nucl Med Biol; 1996 May 22; 23(4):467-71. PubMed ID: 8832701
    [Abstract] [Full Text] [Related]

  • 17. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF.
    Nucl Med Biol; 2006 Aug 22; 33(6):685-94. PubMed ID: 16934687
    [Abstract] [Full Text] [Related]

  • 18. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M, Desmond TJ, Albin RL, Frey KA.
    Synapse; 2001 Sep 15; 41(4):329-36. PubMed ID: 11494403
    [Abstract] [Full Text] [Related]

  • 19. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.
    Zucker M, Weizman A, Rehavi M.
    Life Sci; 2001 Sep 28; 69(19):2311-7. PubMed ID: 11669473
    [Abstract] [Full Text] [Related]

  • 20. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter.
    Efange SM.
    FASEB J; 2000 Dec 28; 14(15):2401-13. PubMed ID: 11099458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.